
Long-term gantenerumab Alzheimer's trial halted due to 'no regulatory path'
Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer's disease (DIAD). Gantenerumab was associated with serious safety concerns, including a high incidence …